BrainStorm Selected as Buzz of BIO 2020 Winner
December 11 2019 - 5:00AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the
development of innovative autologous cellular therapies for highly
debilitating neurodegenerative diseases, today announced, that it
was selected as the Buzz of BIO, in the Public Therapeutics Biotech
category, and due to extensive voter participation
BrainStorm also received an invitation to make a complimentary
company presentation at the BIO CEO & Investor Conference,
to be held in New York City on February 10-11, 2020.
The Buzz of BIO contest provides an excellent
opportunity for companies looking to make the connections needed to
take their product to the next phase. The contest helps to identify
U.S. based companies with groundbreaking, early stage technologies
that have the overall potential to improve lives. Qualifying
biotechs were nominated in each of the three categories: Public
Therapeutic Biotech; Private Therapeutic Biotech; and Diagnostics
and Beyond.
Chaim Lebovits, President and CEO of BrainStorm
Cell Therapeutics said, “Thanks to everyone who voted for
BrainStorm during the Buzz of BIO competition. This
recognition, over all other nominated publicly traded companies,
offers BrainStorm a complimentary presentation at the BIO CEO &
Investor Conference in New York City, February 10-11, 2020. The
entire management team at BrainStorm was very pleased with the
results of this competition and we look forward to presenting to an
audience of accredited investors who may benefit from the Company’s
story. We thank the BIO team for singling out BrainStorm’s NurOwn®
as a key technology with the potential to improve lives. 2019
was a banner year for BrainStorm and we will continue to share our
story with the widest possible audience in 2020.”
About NurOwn®
NurOwn® (autologous MSC-NTF) cells represent a
promising investigational therapeutic approach to targeting disease
pathways important in neurodegenerative disorders. MSC-NTF cells
are produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. BrainStorm has
fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells
for the treatment of amyotrophic lateral sclerosis (ALS).
BrainStorm also received U.S. FDA acceptance to initiate a Phase 2
open-label multicenter trial in progressive MS and enrollment began
in March 2019.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading
developer of innovative autologous adult stem cell therapeutics for
debilitating neurodegenerative diseases. The Company holds the
rights to clinical development and commercialization of the NurOwn®
technology platform used to produce autologous MSC-NTF cells
through an exclusive, worldwide licensing agreement. Autologous
MSC-NTF cells have received Orphan Drug status designation from the
U.S. Food and Drug Administration (U.S. FDA) and the European
Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a
Phase 3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six sites in
the U.S., supported by a grant from the California Institute for
Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is
intended to support a filing for U.S. FDA approval of autologous
MSC-NTF cells in ALS. For more information, visit BrainStorm's
website at www.brainstorm-cell.com.
Safe-Harbor Statements
Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may," "should," "would,"
"could," "will," "expect," "likely," "believe," "plan," "estimate,"
"predict," "potential," and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
BRAINSTORM CONTACTS: Investors: Uri Yablonka,
Chief Business Officer BrainStorm Cell Therapeutics Inc. Phone:
+1-201-488-0460 Email: uri@brainstorm-cell.com
Media: Sean Leous Westwicke/ICR PR Phone: +1.646.677.1839
Email: sean.leous@icrinc.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024